2. Immunology/Inflammation
  3. Interleukin Related
  4. Reslizumab

Reslizumab  (Synonyms: Sch 55700)

Cat. No.: HY-P9949 Purity: 99.4%
COA

Molarity Calculator

Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively.

For research use only. We do not sell to patients.

CAS No. : 241473-69-8

Size Price Stock Quantity
1 mg USD 1000 In-stock
2 mg USD 1800 In-stock
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Reslizumab Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2].

Isotype

Human IgG4 kappa
Recommend Isotype Controls
Species

Humanized
IC50 & Target[1][2]

IL-5

91.1 pM (IC50)

In Vitro

Reslizumab (Sch 55700) (0-10 nM, 48 h) inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reslizumab Related Antibodies

Cell Proliferation Assay[1]

Cell Line: Human erythroleukemic TF-1 cell line
Concentration: 0-10 nM
Incubation Time: 48 h
Result: Showed antiproliferative activity with an IC50 of 91.1 pM.
In Vivo

Reslizumab (Sch 55700) (0-10 mg/kg; i.p. or i.m.) inhibits pulmonary eosinophilia in a dose-dependent manner in allergic mice[3].
Reslizumab (0.03-30 mg/kg; i.p.) inhibits both the pulmonary eosinophilia and airway hyperresponsiveness, and at 30 mg/kg, i.p. inhibits allergic, but not histamine-induced bronchoconstriction in allergic guinea pigs[3].
Reslizumab (0.1-1 mg/kg; i.p.) blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs[3].
Reslizumab (0.3 mg/kg; i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months in allergic cynomolgus monkeys[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male B6D2F1/J mice weighing 20−25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 µg of ovalbumin (OVA) adsorbed to 2 mg of aluminum hydroxide gel in saline vehicle)[3]
Dosage: 0−10 mg/kg
Administration: Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.)
Result: Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (HY-17463).
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Reslizumab]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Purity & Documentation

Purity: 99.4%

COA (291 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Reslizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Reslizumab241473-69-8Sch 55700Sch55700Sch-55700Interleukin RelatedILeosinophilic asthmapulmonary eosinophiliaairway hyperresponsivenessInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Reslizumab
Cat. No.:
HY-P9949
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.